Setting exposure standards: a decision process. by Tilson, H A et al.
Setting Exposure Standards:
A Decision Process
Hugh A. Tilson, Robert C. MacPhail, and
Kevin M. Crofton
Neurotoxicology Division, National Health and Environmental Effects
Research Laboratory, U.S. Environmental Protection Agency, Research
Triangle Park, North Carolina
Increased emphasis on routine screening of chemicals for potential neurotoxicity has resulted in
the development of testing guidelines and standardized procedures. A multiphased, tiered-testing
strategy has been proposed by numerous expert panels to evaluate large numbers of chemicals.
In a regulatory context, however, a formal tiered-testing approach is not used, mostly because of
the constraints of differing regulatory authorities and the potential cost of such a testing strategy.
Instead, current regulatory decision making utilizes all available animal and human data to identify
a critical adverse effect which is then used for setting standards. Although the current decision-
making process does not use a formal tiered-testing approach, it appears to identify chemicals
with neurotoxic effects. An analysis of U.S. Environmental Protection Agency integrated risk
information system (IRIS) indicates that about 20% of the chemicals having standards or health
advisories are based on neurotoxicity. Environ Health Perspect 104(Suppl 2):401-405 (1996)
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Introduction
There are between 50,000 and 100,000
chemicals used commercially and 1,000 to
1,600 newchemicals are submitted for pre-
manufacture notification each year in the
United States alone (1). Several regulatory
agencies in the United States are charged
with enforcing legislation designed to pro-
tect the public and environment from the
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hazards ofchemical exposure (2). Premarket
testing, for example, is required for pesti-
cides by the U.S. Environmental Protection
Agency (U.S. EPA) under the Federal
Insecticide, Fungicide and Rodenticide Act
(FIFRA) and for drugs and food additives
by the Food and Drug Administration
(FDA). The Consumer Product Safety
Commission (CPSC) and U.S. EPA can
require testing of consumer products and
industrial chemicals ifthere is a demon-
strated justification for testing. The U.S.
EPA can also require evaluation ofindus-
trial chemicals under the Toxic Substances
Control Act (TSCA).
It is now recognized that many chemi-
cals can have an adverse effect on the func-
tion and/or structure of the nervous
system. Anger and Johnson (3), for exam-
ple, identified more than 750 industrial
chemicals as having neurotoxic effects fol-
lowing acute or repeated exposure. From
the list of750 chemicals, Anger (4) found
65 chemicals for which it has been esti-
mated that 1 million or more people are
potentially exposed. Of 588 chemicals
listed by the American Conference of
Government and Industrial Hygienists, 167
have threshold limit values based, in part,
on neurologic or behavioral end points (5).
Neurotoxic disorders, hearing loss, and
psychological dysfunction are among the
10 leading occupational problems in the
workplace (6). A recent publication from
the Office ofTechnology Assessment esti-
mated that 3 to 28% ofall chemicals may
be neurotoxic (7).
To identify agents producing neuro-
toxic effects, considerable efforts have been
made to develop valid, sensitive measures
of neurotoxicity. Many of the tests cur-
rently used in neurotoxicological studies
are functional indicators ofneurotoxicity,
especially behavioral end points, that assess
chemical-induced changes in sensory, motor
and cognitive functions. Since behavior
appears to be the net result ofthe integrated
output ofsensory, motor and cognitive
processes ofthe nervous system, chemical-
induced changes in behavior may be a rela-
tively sensitive indicator ofdysfunction in
the nervous system (8).
Reliance on behavioral measures in
neurotoxicological testing is reflected in the
testing guidelines published by regulatory
agencies such as the U.S. EPA. For several
years, the U.S. EPA has had guidelines for
a functional observational battery (FOB),
motor activity, and schedule-controlled
behavior. A neurotoxicity screening battery
(9) consisting ofmotor activity, FOB, and
neuropathology is now required for the
registration and reregistration ofpesticides.
The U.S. EPA has also published testing
guidelines for developmental neurotoxicity
that include motor activity, learning/mem-
ory, and acoustic startle reactivity. The
U.S. EPA also relies on behavioral end
points in screening chemicals that produce
organophosphate-induced delayed neu-
ropathology. In the assessment ofhuman
therapeutic agents, the FDArelies on a bat-
tery ofanimal toxicity data that includes
clinical observations and neuroanatomical
assessments. Neurotoxicity, including
adverse effects on behavior, is ofconcern to
other regulatory agencies, including the
National Institute for Occupational Safety
and Health, Occupational Safety and
HealthAdministration, and the CPSC.
Countries other than the United States
also require behavioral tests in animal toxic-
ity studies. As early as 1975, Great Britain
and Japan began requiring behavioral test-
ing in animals to evaluate thedevelopmental
neurotoxicity ofnewdrugs (10). In adopted
testingprotocols similar to those requiredby
Great Britain andJapan. The World Health
Organization has also published proposed
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testing guidelines for drugs and other
agents. Finally, the Organization for
Economic Cooperation and Development
is now considering a number ofneurotoxic-




Since 1975, a number of expert panels
have recommended a tiered-testing strategy
for the evaluation ofchemicals for neuro-
toxicity, and all have recommended the use
ofbehavioral techniques (11,12) (Table 1).
Tiered testing involves two or more phases
ofevaluation in which each stage incorpo-
rates decision points as to whether available
information is sufficient for determining
the neurotoxicity ofa chemical.
In 1978, Evans and Weiss (13)
described a multiphased strategy of assess-
ment based on a scheme published by the
National Academy ofSciences in 1975 (8)
(Figure 1). In cases where little toxicologi-
cal information exists, there is a need to
first determine whether a chemical is capa-
ble ofproducing neurotoxicity, i.e., hazard
identification. Frequently, an LD50 (or
equivalent) and a chemical's structure are
all that are available in the early stages of
hazard identification. In such cases, assess-
ments at the first tier may be required or a
decision must be made to develop a toxico-
logical profile before subsequent product
development can proceed.
First-tier tests are typified by the capa-
bility to assess large numbers ofanimals,
they usually require little or no training of
test animals before exposure, and they are
relatively simple to perform. Such tests,
however, may be labor intensive, subjective,
and at best semiquantitative. Examples of
first-tier tests include neurological screens
such as the FOB and cage-side observa-
tions. Motor activity is another example of
a first-tier test that is, in contrast to others,
Table 1. Expert panels or committees recommending
neurotoxicitytesting.
Study Year Recommendation
NRC 1975 Tieredtesting using
behavioral tests
NRC 1977 Conditioned and unconditioned
testsforhazard identification
NRC 1984 Behavior and neuropathology
asTier 1 tests
WHO/IPCS 1986 Two tiers of behavioral tests
U.S. EPA/FIFRA 1987 Motoractivity, FOB, and
neuropathology as
Tier 1 testfor pesticides
objective and quantitative (14). Behavioral
tests are sometimes also usedwith other rou-
tine measures such as neuropathology or
neurochemical assays. Ifa chemical is found
to be neurotoxic in the first tier, a decision
would have to be made to test at the next
tier. Such a decision might be based on the
beneficial properties ofthe chemical relative
to the neurotoxic effects observed in the
screening battery. Positive findings in the
first tier, then, could either suspend further
development ofa chemical or facilitate the
design ofexperiments at the next tier.
Studies at the second tier are designed
to characterize the nature ofa chemical's
neurotoxicity. A decision to test at the sec-
ond tier might be based on results from the
first tier, on published data, or on new tox-
icological data indicating that a chemical
already in the environment or workplace
produces neurotoxicity. Second-tier tests
(_Proceed_)
Figure 1. Three-tiered testing scheme recommended
by Evans and Weiss (13) including a first tier for haz-
ard identification, a second tier for characterization of
specific functions, and a third tier for human suscepti-
bility.
are generally thought to be more sensitive
than those at the first tier and can require
special automated equipment and extensive
training ofthe animals. Examples ofsecond-
tier tests include procedures to measure
chemical-induced alterations in learning and
memory or signal detection techniques to
measure sensorydysfunction.
Evans and Weiss (13) also indicated a
third tier oftesting involving assessment of
human susceptibility to environmentally
relevant chemicals using procedures studied
in animals. Fine motor disturbances pro-
duced by exposure to methylmercury, for
example, could be studied in humans using
essentially the same methodology used in
laboratory animals.
In a recent report published by the
National Research Council (15), tiered
testing was also discussed as a strategy for
the assessment of chemicals. The tiered
testing approach is similar to that described
by Evans and Weiss (13) for the first two
tiers. The NRC (15) report, however, indi-
cated that mechanistic studies focusing on
how a chemical produced a neurotoxic
effect would be conducted at the third tier
(Table 2). In this case, a detailed examina-
tion would be undertaken of a chemical's
effect at several levels of nervous system
organization (i.e., behavioral, cellular, mol-
ecular). Information derived from these
studies might be used in the development
ofbiologically based dose-response mod-
els. The approach taken by Choi (16) link-
ing the neurotoxicity produced by an
excitatory amino acid-mediated increase in
intracellular calcium is an example of a
mechanistic study.
In a recent overview of screening
approaches, Tilson and Moser (17) found
similar tier-testing approaches by a number
oflaboratories engaged in animal testing.
All ofthe laboratories surveyed used some
type ofFOB or clinical neurological assess-
ment at the first tier. Specialized measures
of motor function, such as strength, splay
and activity, and routine neuropathology
were included in the first tier by some lab-
oratories. Second-tier evaluations were
used to characterize neurotoxicity detected
in the first tier and included more special-
ized behavioral, neuropathological, electro-
physiological, or neurochemical assays.
Table 2.Tier-testing approach.
Tier 1 Hazard identification
Tier 2 Characterization
Tier3 Mechanism ofaction
Data from the National Research Council (15).
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Several measures at different levels ofneural
organization were frequently taken to vali-
date or improve interpretation ofthe toxi-
cological findings. Since the focus of the
review by Tilson and Moser (17) was on
hazard identification, a third tier oftesting
to assess human neurotoxicity or conduct
mechanistic studies was not discussed.
Tiered Testing in a Decision-
making Context
Although a systematic tiered-testing strategy
as described by Evans and Weiss (13) and
the NRC (15) seems logical and relatively
straightforward in principle, such an
approach is not frequently used in a regula-
tory decision-making context. For example,
although a U.S. EPA testing guideline for
developmental neurotoxicology has been in
place for a number ofyears, it has been
invoked only rarely (18). Instead, U.S. EPA
has historically chosen to use the develop-
mental neurotoxicity guideline in test rules
and negotiated consent agreements where
only a single level oftesting was outlined
(19). A positive finding in such studies in a
regulatory context would very likely not
result in further testing.
One example ofa tier-testing approach
that has been adopted by the U.S. EPA is
in the registration regulations for fuels and
fuel additives. Recently, the U.S. EPApub-
lished a notice ofproposed rule making for
fuels and fuel additives registration regula-
tions (20). The purpose of the proposed
regulation was to establish a requirement
for the registration of motor-vehicle fuels
and fuel additives as authorized by sections
of the amended Clean Air Act. Under the
proposed regulations, makers offuels and
fuel additives would be required to con-
duct tests and submit information regard-
ing effects fuel emissions might have on
public health andwelfare.
The new proposed registration require-
ments for fuels and fuel additives have
been organized within a three-tiered health
effects structure. At the first tier, makers of
fuels and fuel additives would be required
to conduct a literature search on the health
and welfare effects offuel and fuel additive
emissions, characterize the emissions and
provide exposure information. Short-term
biological testing to screen for specific
health effects in animals ofwhole emissions
offuels or fuel additive mixtures would be
performed at the second tier. Neurotoxico-
logical end points include neuropathology
and assessment ofbrain glial fibrillary acid
protein, a putative marker ofneural injury.
At the third tier, U.S. EPAwould determine
on a case-by-case basis ifadditional testing
were needed based on data submitted from
the first two tiers and any other data avail-
able. Information developed under the first
two tiers would be used to provide the req-
uisite information for registration, subject
to subsequent satisfaction ofany tier-three
requirements determined by the U.S. EPA.
Although a formal tier-testing strategy
is not routinely employed in regulatory
decision making, it is clear regulatory deci-
sions are based on data obtained from pro-
cedures normally defined as being first- or
second-tier tests. For example, for some
chemicals regulated under TSCA, the only
available information is the structure and
some estimation ofthe levels and numbers
ofpeople that might be exposed (21). A
decision to require testing might be based
on structure-activity relationships, produc-
tion levels, and proposed use. Tier-one
tests such as an FOB, motor activity, and
neuropathology might be used to provide
the data in such cases. On the other hand,
ifthere are data that suggest neurotoxicity
or ifthe chemical is already on the market
and neurotoxicity has been reported in
occupational or environmental settings,
then testing might be required; depending
on the circumstances, first- and/or second-
tier tests might be used to characterize the
nature ofthe neurotoxicity.
The use ofdata from first- or second-
tier testing in a decision-making context is
dependent on the process by which regula-
tory risk assessments are performed. At the
U.S. EPA, quantitative risk assessment
begins with the definition of a critical
adverse effect based on evaluation ofall the
available human and animal data (Figure
2). Determination of an adverse critical
effect is based on data obtained from ani-
mal experiments using first- and/or second-
tier tests, mechanistic studies, or from
human epidemiological, clinical, or case
studies, from which a critical study is
identified. The critical effect from that
study along with supporting data are then
used to determine a lowest observed adverse
effect level (LOAEL) or no observed
adverse effect level (NOAEL) to calculate a
reference dose (RfD) for regulatory decision
making. The RfD is an estimate ofa daily
exposure to the human population that is
likely to be without appreciable risk over a
lifetime (22) and has historically been
derived bydividing the NOAEL or LOAEL
by one or more factors of up to 10 to
account for one or more uncertainties in
the experimental data. These uncertainty
factors (UF) include intraspecies (human)
Animal data Human data
Tier 1 detection Epidemiology
Tier 2 characterization Case studies










Figure 2. Data from all tiers of animal testing and all
human data from epidemiology, case studies, or clini-
cal observations and experimental studies are evalu-
ated and a critical adverse effect is determined to
calculate standards for regulatory action.
sensitivity, animal-to-human extrapolation,
less-than-lifetime exposures, and use ofa
LOAEL rather than a NOAEL. An addi-
tional uncertainty factor for an incomplete
dataset has also been used. Amodifying fac-
tor ranging from 1 to 10 may also be used
in the denominator to reflect any uncer-
tainties in the critical studyused to establish
the critical effect (22,23).
It is unlikely that the data used to
determine the critical adverse effect would
be derived from a formal systematic tier-
testing strategy. From an industry or pesti-
cide registrant's point ofview, the outcome
of further testing along with the added
time and expense may create disincentives
for tiered testing. Consider the hypotheti-
cal example in Figure 3. The results of
first-tier screening studies suggest a chemi-
cal has neurotoxic potential. Second-tier
testing is then undertaken to characterize
the chemical's neurotoxic effects. If the
results ofsecond-tier testing do not indicate
neurotoxicity, it may be doubtful whether a
prudent risk assessor would summarily dis-
miss the first-tier results. On the otherhand,
ifthe results ofsecond-tier testing indicate
neurotoxicity, the NOAEL or LOAEL may
be either equal to or lower than that estab-
lished on the basis offirst-tier testing. Ifit is
equal then the RfD would be equal, while if
it is lower the RfD would be correspond-
ingly lower. Additional resources would
then have been spent either not to change or
to lowerthe regulatorystandard.
Since a formal tiered-testing strategy is
not currently employed by regulatory agen-
cies such as the U.S. EPA, it is relevant to
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Figure 3. Hypothetical scenario for standard setting
based on a tiered testing approach. The conservative
nature of standard setting, based upon fundamental
uncertainties in predicting human risk, may lead to
selection of the lowest NOAEL regardless of the level
oftesting.
ask about the capability of the current
system to detect and set standards for chem-
icals having neurotoxic effects. To deter-
mine this, the integrated risk information
system (IRIS) ofthe U.S. EPAwas accessed,
and the use ofneurotoxicological findings in
establishing standards and health advisories
(HAs) was determined. IRIS is a computer-
ized database designed by the U.S. EPA's
Office of Health and Environmental
Assessment for use by staff at U.S. EPA
Table 3. Neurotoxicological findings in IRIS databasea.
Standard/advisory Total number ofchemicals Chemicals with neurotoxic end pointsb % Neurotoxic
RfDs 336 65 19.4
RfCs 32 12 37.5
1-Daychild HA 13 6 46.1
10-Daychild HA 35 7 20.0
Longerterm child HA 37 7 18.9
Longerterm Adult HA 37 7 18.9
DWEL/life-time HA 57 11 19.3
'As ofJanuary 1994. bChemicals forwhich critical effect was based wholly or in part on neurotoxic end points.
program offices and research centers to
inform U.S. EPA personnel concerning the
regulatory status ofspecific chemicals.
The IRIS database provides detailed
information concerning the adverse effects
used to generate standards and HAs. Table
3 summarizes the number of chemicals
contained in the database for each category
ofstandards or HAs. Ofthe 336 chemicals
for which there were RfDs, 65 or 19.4%
listed neurotoxicity as the scientific data
used wholly or in part for regulation. Of
the 32 chemicals having inhalation refer-
ence concentrations (RfCs), which are
equivalent to RfDs, 12 or 37.5% were
based on neurotoxicity. Neurotoxicity was
also listed for a number of 1-Day Child
HAs (46.1%), 10-Day Child HAs (20%),
Longer-Term Child HAs (18.9%), Longer-
Term Adult HAs (18.9%), and Lifetime
HAs (19.3%). The percentage ofchemicals
identified as having neurotoxic effects in
IRIS compares favorably with the estimates
reported by the OTA (7) that 3 to 28% of
all chemicals in the environment may be
neurotoxic. The chemicals identified in the
IRIS database included a number ofsol-
vents (e.g., styrene, toluene, xylenes,
acrylamide, n-hexane, propylene glycol
monomethyl ether), pesticides (e.g., carbo-
furan, methyl parathion, pydrin, thiram,
methamidophos), and metals (e.g., man-
ganese, methylmercury).
Therefore, in spite of the lack of a
tiered-testing strategy, neurotoxic effects
are used by the U.S. EPA as the basis for
setting standards and health advisories.
Summary and Conclusions
A tier-testing strategy for the assessment of
neurotoxicity has been proposed by numer-
ous expert panels and, most recently, by the
NRC (15). Although such a testing strategy
is conceptually attractive, it is not practical
in most regulatory contexts. The current
decision-making process at U.S. EPA uti-
lizes all available animal data collected in
hazard identification, characterization, or
mechanism-of-action studies, as well as
human epidemiological, case, and clinical
studies, to arrive at a critical adverse effect.
The risk assessment process then utilizes the
critical adverse effect to support regulatory
decision making. Considering the propor-
tion ofcases in which neurotoxicity is used
as the critical adverse effect, the current
risk assessment system identifies about
20% ofthe chemicals listed as neurotoxic,
which agrees well with the range ofvalues
suggested by the OTA (7). As more is
learned about the mechanism ofaction of
neurotoxic chemicals, future testing may
evolve into a modified tier-testing strategy
where short-term, in vitro tests are used at
the first tier and information from these
studies is used to determine iftesting at the
second tier should occur. Second-tier tests
would indude in vivo tests selected on the
basis ofthe results ofthe first tier.
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